Vécsei L - Search Results

1

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists.

Szűcs E, Stefanucci A, Dimmito MP, Zádor F, Pieretti S, Zengin G, Vécsei L, Benyhe S, Nalli M, Mollica A. Szűcs E, et al. Among authors: vecsei l. Biomolecules. 2020 Feb 12;10(2):284. doi: 10.3390/biom10020284. Biomolecules. 2020. PMID: 32059524 Free PMC article.

2

Role of kynurenines in the central and peripheral nervous systems.

Németh H, Toldi J, Vécsei L. Németh H, et al. Among authors: vecsei l. Curr Neurovasc Res. 2005 Jul;2(3):249-60. doi: 10.2174/1567202054368326. Curr Neurovasc Res. 2005. PMID: 16181118 Review.

3

Kynurenines, neurodegeneration and Alzheimer's disease.

Kincses ZT, Toldi J, Vécsei L. Kincses ZT, et al. Among authors: vecsei l. J Cell Mol Med. 2010 Aug;14(8):2045-54. doi: 10.1111/j.1582-4934.2010.01123.x. Epub 2010 Jul 12. J Cell Mol Med. 2010. PMID: 20629991 Free PMC article. Review.

4

Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.

Zádor F, Lénárt N, Csibrány B, Sántha M, Molnár M, Tuka B, Samavati R, Klivényi P, Vécsei L, Marton A, Vizler C, Nagy GM, Borsodi A, Benyhe S, Páldy E. Zádor F, et al. Among authors: vecsei l. Neuropharmacology. 2015 Feb;89:298-307. doi: 10.1016/j.neuropharm.2014.10.008. Neuropharmacology. 2015. PMID: 25446673 Free article.

5

Inhibition of opioid receptor mediated G-protein activity after chronic administration of kynurenic acid and its derivative without direct binding to opioid receptors.

Zador F, Samavati R, Szlavicz E, Tuka B, Bojnik E, Fulop F, Toldi J, Vecsei L, Borsodi A. Zador F, et al. Among authors: vecsei l. CNS Neurol Disord Drug Targets. 2014;13(9):1520-9. doi: 10.2174/1871527314666141205164114. CNS Neurol Disord Drug Targets. 2014. PMID: 25478797

6

Kynurenic acid and its analogue can alter the opioid receptor G-protein signaling after acute treatment via NMDA receptor in rat cortex and striatum.

Samavati R, Zádor F, Szűcs E, Tuka B, Martos D, Veres G, Gáspár R, Mándity IM, Fülöp F, Vécsei L, Benyhe S, Borsodi A. Samavati R, et al. Among authors: vecsei l. J Neurol Sci. 2017 May 15;376:63-70. doi: 10.1016/j.jns.2017.02.053. Epub 2017 Feb 27. J Neurol Sci. 2017. PMID: 28431630

7

Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.

Nagy-Grócz G, Zádor F, Dvorácskó S, Bohár Z, Benyhe S, Tömböly C, Párdutz Á, Vécsei L. Nagy-Grócz G, et al. Among authors: vecsei l. Int J Mol Sci. 2017 Jul 30;18(8):1617. doi: 10.3390/ijms18081617. Int J Mol Sci. 2017. PMID: 28758944 Free PMC article. Review.

8

Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects.

Hertelendy P, Toldi J, Fülöp F, Vécsei L. Hertelendy P, et al. Among authors: vecsei l. Curr Med Chem. 2018;25(42):5945-5957. doi: 10.2174/0929867325666180313113411. Curr Med Chem. 2018. PMID: 29532751 Review.

9

Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions.

Zádor F, Nagy-Grócz G, Kekesi G, Dvorácskó S, Szűcs E, Tömböly C, Horvath G, Benyhe S, Vécsei L. Zádor F, et al. Among authors: vecsei l. Molecules. 2019 Oct 15;24(20):3709. doi: 10.3390/molecules24203709. Molecules. 2019. PMID: 31619006 Free PMC article. Review.

10

Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism.

Tanaka M, Bohár Z, Vécsei L. Tanaka M, et al. Among authors: vecsei l. Molecules. 2020 Jan 28;25(3):564. doi: 10.3390/molecules25030564. Molecules. 2020. PMID: 32012948 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

699 results

Search Page